Reuters: Regulatory News: UPDATE 1-Somaxon keeps insomnia drug exclusivity till 2020

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Somaxon keeps insomnia drug exclusivity till 2020 Jul 17th 2012, 22:26 Tue Jul 17, 2012 6:26pm EDT * Grants Mylan right to sell generic Silenor from January 2020 * Settles patent suit with Par Pharmaceutical * Somaxon shares jump 146 percent after market July 17 (Reuters) - Somaxon Pharmaceuticals Inc protected the market exclusivity for its insomnia treatment till 2020 by settling separate patent lawsuits with Mylan Pharmaceuticals and Par Pharmaceutical Cos Inc. Somaxon shares jumped 146 percent on the news in extended trading. They closed at 26 cents on Tuesday on the Nasdaq. The settlement gives Mylan the right to sell a generic version of Silenor -- an insomnia treatment -- from Jan. 1, 2020 or earlier under certain circumstances for a period of 180 days. Mylan's right to sell the product could extend for a period of 360 days, and will have the non-exclusive right to sell a generic version of the drug after the period. Somaxon said Mylan has agreed to supply the company with commercial quantities of Silenor 3 mg and 6 mg tablets. Somaxon, which also struck a deal with Par Pharmaceutical, gave the generic drugmaker the right to market a copycat version of the drug 180 days after a generic version of Silenor is sold in the United States by a third party. Silenor, which is the only source of revenue for Somaxon, is expected to rake in sales of about $2.8 million to $2.9 million in the second quarter, the company said. The San Diego, California-based company, which in December said it was exploring strategic alternatives that included a sale, sold $2.7 million worth Silenor in the first quarter. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions